Positive Phase III results with Avastin in breast cancer patients

被引：0
|
作者：
不详
机构：
来源：
IMMUNOTHERAPY | 2009年 / 1卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：13 / 13
页数：1
相关论文
共 50 条
  • [41] Phase III comparative study of trastuzumab and paclitaxel with and without carboplatin in patients with HER-2/neu positive advanced breast cancer.
    Robert, N
    Leyland-Jones, B
    Asmar, L
    Belt, R
    Ilegbodu, D
    Loesch, D
    Raju, R
    Valentine, E
    Sayre, R
    Albain, K
    Cobleigh, M
    McCullough, C
    Fuchs, L
    Slamon, D
    BREAST CANCER RESEARCH AND TREATMENT, 2002, 76 : S37 - S37
  • [42] Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
    Mary E. Peterson
    Supportive Care in Cancer, 2013, 21 : 2341 - 2349
  • [43] Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
    Peterson, Mary E.
    SUPPORTIVE CARE IN CANCER, 2013, 21 (08) : 2341 - 2349
  • [44] Oral Immunotherapy for Peanut Allergy: positive Results in Phase III Study
    不详
    ALLERGO JOURNAL, 2023, 32 (02) : 55 - 55
  • [45] ADDITIONAL SAFETY RESULTS OF HANNAH: A PHASE III RANDOMISED, OPEN-LABEL, INTERNATIONAL STUDY OF THE SUBCUTANEOUS FORMULATION OF TRASTUZUMAB (H) IN HER2-POSITIVE EARLY BREAST CANCER PATIENTS
    Jackisch, C.
    Dank, M.
    Frasci, G.
    Park, K. H.
    Lopez, R. I.
    Johnston, M.
    Heinzmann, D.
    Weber, H.
    Ismael, G.
    ANNALS OF ONCOLOGY, 2012, 23 : 102 - 103
  • [46] Autoimmunity and benefit from trastuzumab treatment in breast cancer: Results from the HERA phase III trial
    Sonnenblick, A.
    Bailey, A.
    Uziely, B.
    Untch, M.
    Smith, I.
    Gianni, L.
    Baselga, J.
    Jackisch, C.
    Cameron, D.
    Bell, R.
    Zardavas, D.
    Al-Sakaff, N.
    Gelber, R.
    Dowsett, M.
    Leyland-jones, B.
    Piccart, M.
    de Azambuja, E.
    ANNALS OF ONCOLOGY, 2018, 29
  • [47] Positive Phase III trial results of Benlysta™ for systemic lupus erythematosus
    不详
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2009, 5 (05) : 495 - 495
  • [48] Positive phase III results for odevixibat for progressive familial intrahepatic cholestasis
    Katrina Ray
    Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 556 - 556
  • [49] Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA
    Swain, S. M.
    Baselga, J.
    Miles, D.
    Im, Y. -H.
    Quah, C.
    Lee, L. F.
    Cortes, J.
    ANNALS OF ONCOLOGY, 2014, 25 (06) : 1116 - 1121
  • [50] Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer
    Veronesi, U.
    Mariani, L.
    Decensi, A.
    Formelli, F.
    Camerini, T.
    Miceli, R.
    Di Mauro, M. G.
    Costa, A.
    Marubini, E.
    Sporn, M. B.
    De Palo, G.
    ANNALS OF ONCOLOGY, 2006, 17 (07) : 1065 - 1071
12345